Lupin gets USFDA nod for biosimilar drug

Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupin’s Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tj2Ivca
via IFTTT

Read More

Sun Pharma brings global psoriasis drug ILUMYA to Indian market

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This novel treatment, Tildrakizumab, has a proven track record globally for providing significant and sustained skin clearance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e5Ki80u
via IFTTT

Read More

Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned Vitabiotics

Indian drugmaker Lupin and private equity firms are exploring the acquisition of UK's Vitabiotics. The deal is valued at approximately one billion pounds. Several Indian companies had previously considered the acquisition but stepped back due to valuation concerns. Vitabiotics' Indian arm, Meyer Vitabiotics, contributes significantly to its annual sales. The nutraceutical market in India is experiencing rapid growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNV1AuZ
via IFTTT

Read More

Torrent Pharma fined Rs 41 crore over alleged wrong GST refund

Torrent Pharmaceuticals has been fined Rs 41 crores by the Central GST Ahmedabad South Commissionerate. The company faces allegations of wrongful refund claims on export of goods. Torrent Pharmaceuticals plans to appeal the order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6HOgYLl
via IFTTT

Read More

Apollo Pharmacy targets 10 crore customer base in 5 years, to open 2 new stores per day: CEO

Apollo Pharmacy plans an aggressive expansion, aiming to open two new stores daily to reach a customer base of 10 crore within five years. Having surpassed 7,000 stores, the omni-channel network seeks to enhance its neighbourhood presence and ensure widespread access to quality medicines. The company also reported its loyalty program, Apollo Circle, has crossed 10 million members.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8JLC52k
via IFTTT

Read More

Generic HIV drug rollout to take a hit on trial push

India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BDUcR9e
via IFTTT

Read More

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Glenmark Pharmaceuticals has received a positive report from the US health regulator. The company's manufacturing facility in Monroe, North Carolina, has been classified as Voluntary Action Indicated. This development means the facility can now restart commercial manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTzZfPs
via IFTTT

Read More